Eupraxia Pharmaceuticals (TSX:EPRX) Tax Rate %: -0.11% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
36 GF Score
Price C$9.10
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals Tax Rate %?

Eupraxia Pharmaceuticals TSX:EPRX +8.59% 36 Tax Rate % is -0.11% as of Mar. 2026. GuruFocus rates TSX:EPRX with a GF Score™ of 36/100. The stock has 1 warning sign investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Eupraxia Pharmaceuticals's Tax Expense for the three months ended in Mar. 2026 was C$0.02 Mil. Eupraxia Pharmaceuticals's Pre-Tax Income for the three months ended in Mar. 2026 was C$-17.34 Mil. Therefore, Eupraxia Pharmaceuticals's Tax Rate % for the quarter that ended in Mar. 2026 was -0.11%.

Eupraxia Pharmaceuticals Tax Rate % Related Terms

Eupraxia Pharmaceuticals Tax Rate % Historical Data

* Premium members only.

The historical data trend for Eupraxia Pharmaceuticals's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals Tax Rate % Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Rate %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 -0.12 -0.01 -0.05

Eupraxia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.07 0.01 -0.07 -0.11
TSX:EPRX
36GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
Tax Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eupraxia Pharmaceuticals Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Eupraxia Pharmaceuticals's Tax Rate % for the fiscal year that ended in Dec. 2025 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2025 )/Pre-Tax Income (A: Dec. 2025 )
=0.026/-53.231
=-0.05 %

Eupraxia Pharmaceuticals's Tax Rate % for the quarter that ended in Mar. 2026 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2026 )/Pre-Tax Income (Q: Mar. 2026 )
=0.019/-17.343
=-0.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of -0.11% mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a Tax Rate % of -0.11% as of Mar. 2026.
Is Eupraxia Pharmaceuticals' Tax Rate % too high?
Eupraxia Pharmaceuticals' current Tax Rate % is -0.11%. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' Tax Rate % compare to VRTX and REGN?
Eupraxia Pharmaceuticals' Tax Rate % of -0.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. Eupraxia Pharmaceuticals's current Tax Rate % is -0.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current Tax Rate % of -0.11%. The current Tax Rate % is -0.11%. Eupraxia Pharmaceuticals' overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current Tax Rate % is -0.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
36GF Score

Get the complete analysis for TSX:EPRX

Tax Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.10
Price